Concepts (205)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 10 | 2023 | 2440 | 0.750 |
Why?
|
| Atherosclerosis | 6 | 2025 | 1003 | 0.570 |
Why?
|
| Cardiovascular Diseases | 6 | 2024 | 2093 | 0.490 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2018 | 343 | 0.480 |
Why?
|
| Ventricular Dysfunction, Left | 5 | 2023 | 382 | 0.390 |
Why?
|
| Echocardiography | 4 | 2023 | 1132 | 0.310 |
Why?
|
| Cardiology | 2 | 2024 | 521 | 0.290 |
Why?
|
| Healthcare Disparities | 2 | 2025 | 483 | 0.290 |
Why?
|
| Hypertension | 3 | 2024 | 1409 | 0.280 |
Why?
|
| Ventricular Remodeling | 1 | 2008 | 191 | 0.270 |
Why?
|
| Heart Diseases | 2 | 2024 | 523 | 0.260 |
Why?
|
| Atrial Fibrillation | 2 | 2024 | 702 | 0.260 |
Why?
|
| Aortic Stenosis, Subvalvular | 1 | 2005 | 6 | 0.240 |
Why?
|
| Apolipoprotein C-III | 1 | 2025 | 46 | 0.230 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2005 | 55 | 0.230 |
Why?
|
| Health Status Disparities | 2 | 2025 | 252 | 0.230 |
Why?
|
| NF-kappa B | 3 | 2003 | 483 | 0.230 |
Why?
|
| Patient Readmission | 2 | 2018 | 430 | 0.220 |
Why?
|
| Hypertriglyceridemia | 1 | 2025 | 114 | 0.220 |
Why?
|
| Endocarditis | 1 | 2025 | 107 | 0.210 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2005 | 258 | 0.210 |
Why?
|
| Cardiologists | 1 | 2023 | 24 | 0.210 |
Why?
|
| Hypolipidemic Agents | 1 | 2025 | 191 | 0.210 |
Why?
|
| United States | 12 | 2025 | 11798 | 0.210 |
Why?
|
| Income | 1 | 2024 | 140 | 0.200 |
Why?
|
| Carotid Artery Diseases | 2 | 2015 | 148 | 0.200 |
Why?
|
| Cardiovascular System | 1 | 2024 | 110 | 0.200 |
Why?
|
| Vascular Stiffness | 2 | 2015 | 80 | 0.190 |
Why?
|
| Triglycerides | 1 | 2025 | 618 | 0.190 |
Why?
|
| Cause of Death | 1 | 2024 | 506 | 0.190 |
Why?
|
| Aortic Valve | 1 | 2005 | 468 | 0.190 |
Why?
|
| Antihypertensive Agents | 1 | 2024 | 411 | 0.180 |
Why?
|
| Humans | 36 | 2025 | 134225 | 0.180 |
Why?
|
| Hospitalization | 3 | 2024 | 1919 | 0.180 |
Why?
|
| Warfarin | 1 | 2022 | 132 | 0.180 |
Why?
|
| Clinical Trials as Topic | 2 | 2024 | 1161 | 0.170 |
Why?
|
| Adult | 16 | 2025 | 31962 | 0.170 |
Why?
|
| General Practitioners | 1 | 2019 | 18 | 0.160 |
Why?
|
| Myocytes, Cardiac | 1 | 2003 | 663 | 0.150 |
Why?
|
| Middle Aged | 13 | 2025 | 29430 | 0.150 |
Why?
|
| Trypanosoma cruzi | 1 | 2021 | 251 | 0.140 |
Why?
|
| Thrombosis | 1 | 2022 | 547 | 0.140 |
Why?
|
| Chagas Disease | 1 | 2021 | 309 | 0.130 |
Why?
|
| Physicians | 1 | 2023 | 641 | 0.130 |
Why?
|
| Apoptosis | 1 | 2003 | 1945 | 0.130 |
Why?
|
| Cocaine | 1 | 2018 | 208 | 0.130 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2018 | 252 | 0.130 |
Why?
|
| Risk Factors | 7 | 2025 | 11196 | 0.130 |
Why?
|
| Cardiomyopathies | 1 | 2021 | 519 | 0.130 |
Why?
|
| Prevalence | 4 | 2025 | 2685 | 0.120 |
Why?
|
| Male | 18 | 2025 | 66215 | 0.120 |
Why?
|
| Myocardial Infarction | 1 | 2003 | 1098 | 0.120 |
Why?
|
| Female | 19 | 2025 | 72054 | 0.120 |
Why?
|
| Pericardial Window Techniques | 1 | 2015 | 5 | 0.120 |
Why?
|
| Ventricular Dysfunction | 1 | 2015 | 25 | 0.120 |
Why?
|
| Acute Coronary Syndrome | 1 | 2018 | 244 | 0.110 |
Why?
|
| Postprandial Period | 1 | 2015 | 91 | 0.110 |
Why?
|
| Cardiac Tamponade | 1 | 2015 | 38 | 0.110 |
Why?
|
| Patient Education as Topic | 1 | 2018 | 469 | 0.110 |
Why?
|
| Carotid Arteries | 1 | 2015 | 150 | 0.110 |
Why?
|
| Pericardial Effusion | 1 | 2015 | 71 | 0.110 |
Why?
|
| Peptide Fragments | 1 | 2018 | 832 | 0.110 |
Why?
|
| Coronary Artery Disease | 1 | 2021 | 896 | 0.110 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2022 | 808 | 0.100 |
Why?
|
| Hyperlipidemias | 1 | 2015 | 199 | 0.100 |
Why?
|
| Dietary Fats | 1 | 2015 | 300 | 0.100 |
Why?
|
| Aged | 7 | 2025 | 21822 | 0.100 |
Why?
|
| Clinical Competence | 1 | 2019 | 1068 | 0.090 |
Why?
|
| Age of Onset | 2 | 2025 | 638 | 0.090 |
Why?
|
| Carotid Artery, Common | 1 | 2011 | 69 | 0.090 |
Why?
|
| American Heart Association | 2 | 2024 | 329 | 0.090 |
Why?
|
| Breast Neoplasms | 1 | 2024 | 2771 | 0.090 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2013 | 140 | 0.090 |
Why?
|
| Retrospective Studies | 6 | 2025 | 17591 | 0.090 |
Why?
|
| Ventricular Function, Left | 3 | 2023 | 556 | 0.080 |
Why?
|
| Stroke Volume | 2 | 2023 | 535 | 0.080 |
Why?
|
| Inpatients | 2 | 2024 | 551 | 0.080 |
Why?
|
| Membrane Glycoproteins | 2 | 2002 | 432 | 0.080 |
Why?
|
| Receptors, Cell Surface | 2 | 2002 | 498 | 0.080 |
Why?
|
| Risk Assessment | 3 | 2025 | 3754 | 0.080 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2022 | 292 | 0.080 |
Why?
|
| Databases, Factual | 2 | 2025 | 1260 | 0.080 |
Why?
|
| Myocardial Ischemia | 2 | 2021 | 364 | 0.080 |
Why?
|
| Hospital Mortality | 2 | 2025 | 1100 | 0.080 |
Why?
|
| Vena Cava, Superior | 1 | 2009 | 60 | 0.070 |
Why?
|
| Texas | 3 | 2024 | 3719 | 0.070 |
Why?
|
| Prognosis | 3 | 2025 | 5085 | 0.070 |
Why?
|
| Neurotransmitter Agents | 1 | 2008 | 150 | 0.070 |
Why?
|
| Young Adult | 4 | 2024 | 9963 | 0.070 |
Why?
|
| Drosophila Proteins | 2 | 2002 | 773 | 0.060 |
Why?
|
| Time Factors | 3 | 2025 | 6595 | 0.060 |
Why?
|
| Chest Pain | 1 | 2005 | 133 | 0.060 |
Why?
|
| Electric Countershock | 1 | 2024 | 74 | 0.050 |
Why?
|
| Dyspnea | 1 | 2005 | 160 | 0.050 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2003 | 35 | 0.050 |
Why?
|
| Renin-Angiotensin System | 1 | 2024 | 107 | 0.050 |
Why?
|
| Cytoprotection | 1 | 2003 | 39 | 0.050 |
Why?
|
| Age Factors | 2 | 2025 | 2997 | 0.050 |
Why?
|
| I-kappa B Proteins | 1 | 2003 | 42 | 0.050 |
Why?
|
| Lipopolysaccharides | 2 | 2002 | 319 | 0.050 |
Why?
|
| Ligation | 1 | 2003 | 138 | 0.050 |
Why?
|
| Heart Ventricles | 3 | 2022 | 804 | 0.050 |
Why?
|
| Diabetes Mellitus | 1 | 2011 | 938 | 0.050 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2002 | 53 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2013 | 1419 | 0.050 |
Why?
|
| Vitamin K | 1 | 2022 | 39 | 0.050 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2022 | 51 | 0.050 |
Why?
|
| Mortality | 1 | 2024 | 261 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2025 | 13105 | 0.050 |
Why?
|
| Catheter Ablation | 1 | 2024 | 248 | 0.050 |
Why?
|
| Growth Substances | 1 | 2002 | 114 | 0.050 |
Why?
|
| Disease Progression | 1 | 2008 | 2265 | 0.050 |
Why?
|
| Quality Indicators, Health Care | 1 | 2024 | 231 | 0.050 |
Why?
|
| Animals | 7 | 2025 | 36526 | 0.050 |
Why?
|
| Residence Characteristics | 1 | 2024 | 293 | 0.050 |
Why?
|
| Inflammation Mediators | 1 | 2003 | 258 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2008 | 1344 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2024 | 7244 | 0.040 |
Why?
|
| Shock, Septic | 1 | 2002 | 157 | 0.040 |
Why?
|
| Insect Vectors | 1 | 2021 | 114 | 0.040 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2002 | 198 | 0.040 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2002 | 299 | 0.040 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2025 | 460 | 0.040 |
Why?
|
| Echocardiography, Stress | 1 | 2020 | 18 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2021 | 225 | 0.040 |
Why?
|
| Coronary Vessels | 1 | 2003 | 566 | 0.040 |
Why?
|
| Survival Rate | 1 | 2024 | 2214 | 0.040 |
Why?
|
| Comorbidity | 1 | 2024 | 1628 | 0.040 |
Why?
|
| Heart-Assist Devices | 1 | 2008 | 1101 | 0.040 |
Why?
|
| Cholesterol | 1 | 2022 | 574 | 0.040 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2020 | 111 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2002 | 415 | 0.040 |
Why?
|
| Diabetes Complications | 1 | 2020 | 206 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2024 | 1423 | 0.040 |
Why?
|
| Bisoprolol | 1 | 2018 | 12 | 0.040 |
Why?
|
| Atenolol | 1 | 2018 | 43 | 0.040 |
Why?
|
| Propanolamines | 1 | 2018 | 32 | 0.040 |
Why?
|
| Metoprolol | 1 | 2018 | 22 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2023 | 1251 | 0.040 |
Why?
|
| Cerebellum | 1 | 2002 | 467 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2003 | 2538 | 0.040 |
Why?
|
| Propranolol | 1 | 2018 | 131 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2022 | 1196 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 2018 | 76 | 0.030 |
Why?
|
| Telephone | 1 | 2018 | 127 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2022 | 626 | 0.030 |
Why?
|
| Heart | 1 | 2002 | 748 | 0.030 |
Why?
|
| Sex Factors | 1 | 2021 | 1388 | 0.030 |
Why?
|
| Incidence | 1 | 2025 | 3424 | 0.030 |
Why?
|
| Ischemia | 1 | 2020 | 386 | 0.030 |
Why?
|
| Escherichia coli | 1 | 2002 | 1032 | 0.030 |
Why?
|
| Adolescent | 2 | 2024 | 20647 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 681 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2003 | 701 | 0.030 |
Why?
|
| Ultrasonography | 2 | 2015 | 1003 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2013 | 3056 | 0.030 |
Why?
|
| Pulse Wave Analysis | 1 | 2015 | 51 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2015 | 153 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 759 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 567 | 0.030 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2013 | 80 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 3759 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2002 | 93 | 0.020 |
Why?
|
| Cyclic GMP | 2 | 2002 | 105 | 0.020 |
Why?
|
| Nitric Oxide Synthase | 2 | 2002 | 177 | 0.020 |
Why?
|
| Interleukin-1 | 2 | 2002 | 143 | 0.020 |
Why?
|
| Toll-Like Receptors | 2 | 2002 | 85 | 0.020 |
Why?
|
| Mice | 3 | 2003 | 19049 | 0.020 |
Why?
|
| Blood Pressure Determination | 1 | 2011 | 116 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2015 | 1493 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2018 | 1166 | 0.020 |
Why?
|
| Up-Regulation | 2 | 2002 | 914 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 4008 | 0.020 |
Why?
|
| Incidental Findings | 1 | 2009 | 129 | 0.020 |
Why?
|
| Hemodynamics | 2 | 2002 | 871 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 2171 | 0.020 |
Why?
|
| Myocardium | 2 | 2002 | 1041 | 0.020 |
Why?
|
| Algorithms | 1 | 2011 | 1739 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2003 | 79 | 0.010 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2002 | 12 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 2002 | 123 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2002 | 103 | 0.010 |
Why?
|
| Dimerization | 1 | 2002 | 153 | 0.010 |
Why?
|
| Transcription Factor RelA | 1 | 2002 | 57 | 0.010 |
Why?
|
| Immunologic Factors | 1 | 2003 | 186 | 0.010 |
Why?
|
| Echocardiography, Doppler | 1 | 2002 | 174 | 0.010 |
Why?
|
| Biological Transport | 1 | 2002 | 371 | 0.010 |
Why?
|
| Molecular Chaperones | 1 | 2002 | 174 | 0.010 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2002 | 145 | 0.010 |
Why?
|
| Antirheumatic Agents | 1 | 2003 | 124 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2002 | 304 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2009 | 2204 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2002 | 840 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2002 | 691 | 0.010 |
Why?
|
| Cardiac Catheterization | 1 | 2002 | 669 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2002 | 2793 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2002 | 948 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 3978 | 0.010 |
Why?
|
| Cytokines | 1 | 2003 | 1397 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2002 | 1762 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2002 | 2915 | 0.010 |
Why?
|
| Inflammation | 1 | 2002 | 1595 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2002 | 4012 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2002 | 4883 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2002 | 4939 | 0.000 |
Why?
|